| Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer C Twyman-Saint Victor, AJ Rech, A Maity, R Rengan, KE Pauken, ... Nature 520 (7547), 373-377, 2015 | 2096 | 2015 |
| Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy J Li, KT Byrne, F Yan, T Yamazoe, Z Chen, T Baslan, LP Richman, JH Lin, ... Immunity 49 (1), 178-193. e7, 2018 | 478 | 2018 |
| CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients AJ Rech, R Mick, S Martin, A Recio, NA Aqui, DJ Powell Jr, TA Colligon, ... Science translational medicine 4 (134), 134ra62-134ra62, 2012 | 330 | 2012 |
| Clinical use of anti‐CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells AJ Rech, RH Vonderheide Annals of the New York Academy of Sciences 1174 (1), 99-106, 2009 | 324 | 2009 |
| Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction DK Wells, MM van Buuren, KK Dang, VM Hubbard-Lucey, KCF Sheehan, ... Cell 183 (3), 818-834. e13, 2020 | 236 | 2020 |
| Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic CancerImmune Cytolytic Activity and Subsets of Pancreatic Cancer D Balli, AJ Rech, BZ Stanger, RH Vonderheide Clinical Cancer Research 23 (12), 3129-3138, 2017 | 196 | 2017 |
| Lack of immunoediting in murine pancreatic cancer reversed with neoantigen RA Evans, MS Diamond, AJ Rech, T Chao, MW Richardson, JH Lin, ... JCI insight 1 (14), 2016 | 145 | 2016 |
| Tumor cell–intrinsic EPHA2 suppresses antitumor immunity by regulating PTGS2 (COX-2) N Markosyan, J Li, YH Sun, LP Richman, JH Lin, F Yan, L Quinones, ... The Journal of clinical investigation 129 (9), 3594-3609, 2019 | 115 | 2019 |
| Neoantigen dissimilarity to the self-proteome predicts immunogenicity and response to immune checkpoint blockade LP Richman, RH Vonderheide, AJ Rech Cell systems 9 (4), 375-382. e4, 2019 | 95 | 2019 |
| PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial V Narayan, JS Barber-Rotenberg, IY Jung, SF Lacey, AJ Rech, MM Davis, ... Nature medicine 28 (4), 724-734, 2022 | 94 | 2022 |
| Radiotherapy and CD40 activation separately augment immunity to checkpoint blockade in cancer AJ Rech, H Dada, JJ Kotzin, J Henao-Mejia, AJ Minn, ... Cancer research 78 (15), 4282-4291, 2018 | 94 | 2018 |
| Tumor Immunity and Survival as a Function of Alternative Neopeptides in Human CancerAlternative Neopeptides Predict Survival and Immunity AJ Rech, D Balli, A Mantero, H Ishwaran, KL Nathanson, BZ Stanger, ... Cancer immunology research 6 (3), 276-287, 2018 | 71 | 2018 |
| Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast CancerImmunogenetic Signatures of BRCA1/2 Breast Cancer AA Kraya, KN Maxwell, B Wubbenhorst, BM Wenz, J Pluta, AJ Rech, ... Clinical Cancer Research 25 (14), 4363-4374, 2019 | 64 | 2019 |
| Homeostasis of peripheral FoxP3+ CD4+ regulatory T cells in patients with early and late stage breast cancer AJ Rech, R Mick, DE Kaplan, KM Chang, SM Domchek, RH Vonderheide Cancer immunology, immunotherapy 59, 599-607, 2010 | 57 | 2010 |
| Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers EL Carpenter, R Mick, AJ Rech, GL Beatty, TA Colligon, MR Rosenfeld, ... Clinical Cancer Research 15 (13), 4277-4287, 2009 | 56 | 2009 |
| Class I-restricted T-cell responses to a polymorphic peptide in a gene therapy clinical trial for α-1-antitrypsin deficiency R Calcedo, S Somanathan, Q Qin, MR Betts, AJ Rech, RH Vonderheide, ... Proceedings of the National Academy of Sciences 114 (7), 1655-1659, 2017 | 51 | 2017 |
| T-cell transfer therapy targeting mutant KRAS AJ Rech, RH Vonderheide N Engl J Med 376, e11, 2017 | 31 | 2017 |
| Dynamic interplay of oncogenes and T cells induces PD-L1 in the tumor microenvironment AJ Rech, RH Vonderheide Cancer Discovery 3 (12), 1330-1332, 2013 | 29 | 2013 |
| T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma M Barsch, H Salié, AE Schlaak, Z Zhang, M Hess, LS Mayer, C Tauber, ... Journal of hepatology 77 (2), 397-409, 2022 | 25 | 2022 |
| Phase I study of anti-CD25 mab daclizumab to deplete regulatory T cells prior to telomerase/survivin peptide vaccination in patients (pts) with metastatic breast cancer (MBC). AJ Rech, R Mick, A Recio, A DeMichele, CK Tweed, KR Fox, ... Journal of Clinical Oncology 28 (15_suppl), 2508-2508, 2010 | 8 | 2010 |
Michael D FeldmanIndiana UniversityПотвърден имейл адрес: iu.edu
